GlassScriptPhysician profile
Charles A Lively
NPI 1326062589
$3,324.64
in general payments reported to CMS, 2019-2025
23 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $593 · 2021: $875 · 2022: $416 · 2023: $541 · 2024: $347 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $909.04 | 2020-2025 | |
| Lilly USA, LLC | $524.67 | 2019-2025 | Zepbound, Mounjaro, Emgality |
| Galderma Laboratories, L.P. | $281.91 | 2019-2021 | |
| Allergan, INC. | $223.42 | 2019-2022 | |
| Novo Nordisk INC | $149.51 | 2022-2025 | Wegovy, Saxenda |
| Pfizer INC. | $142.10 | 2023-2025 | |
| Zyla Life Sciences, INC. | $130.83 | 2020 | |
| Lupin INC. | $122.71 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $121.17 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $119.22 | 2022-2024 | Quviviq |
| Merz North America, INC. | $100.29 | 2023-2024 | Xeomin |
| Ascend Therapeutics US, LLC | $89.01 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $84.82 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $80.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.73 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $35.06 | 2019-2020 | |
| Lundbeck LLC | $32.90 | 2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $32.22 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $25.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $25.00 | 2019-2023 | Bridion |
| Supernus Pharmaceuticals, INC. | $24.28 | 2021 | |
| Myovant Sciences INC. | $15.52 | 2021 | |
| Avion Pharmaceuticals | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lively listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.